会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • 포유류의 탯줄유래 줄기세포 분리 또는 배양용 배지 조성물, 그리고 이를 이용한 포유류의 탯줄유래 줄기세포 분리 또는 배양 방법
    • 用于分离或培养MAMMALIAN脐带血干细胞的介质,以及分离或培养MAMMALIAN脐带干细胞的方法
    • KR1020130008178A
    • 2013-01-22
    • KR1020110068761
    • 2011-07-12
    • (주)차바이오텍(주)차바이오메드의료법인 성광의료재단
    • 최용수김선미김호진이영준한규범정형민
    • C12N5/074C12Q1/02C12Q1/25
    • PURPOSE: A medium composition for isolating and culturing mammalian umbilical cord-derived stem cells is provided to quickly obtain a large amount of stem cells with excellent proliferation and differentiation abilities. CONSTITUTION: A medium composition for isolating or culturing mammalian umbilical cord-derived stem cells contains an umbilical cord extract without serum. Mammal includes human, pig, horse, cow, mouse, rat, hamster, rabbit, goat, or sheep. A method for preparing the umbilical cord extract comprises: a step of adding cut umbilical cord to a buffer solution and stirring; and a step of collecting supernatant from the mixed solution. A method for preparing the stem cells from the mammalian umbilical cord comprises: a step of culturing a blood-removed umbilical cord tissue in a container which is coated with a cell adhesion protein and contains the medium composition; and a step of treating the tissue with a medium containing stem cell lysis enzyme and isolating the stem cells. The cell adhesion protein includes mammalian umbilical cord-derived collagen, gelatin, fibronectin, laminin, or poly-D-lysine.
    • 目的:提供用于分离和培养哺乳动物脐带血干细胞的培养基组合物,以快速获得大量具有优异增殖和分化能力的干细胞。 构成:用于分离或培养哺乳动物脐带源干细胞的培养基组合物含有不含血清的脐带提取物。 哺乳动物包括人,猪,马,牛,老鼠,大鼠,仓鼠,兔,山羊或绵羊。 制备脐带提取物的方法包括:将切割的脐带加入缓冲溶液并搅拌的步骤; 以及从混合溶液中收集上清液的步骤。 用于从哺乳动物脐带制备干细胞的方法包括:在包被细胞粘附蛋白并容纳培养基组合物的容器中培养除血的脐带组织的步骤; 以及用含有干细胞裂解酶的培养基处理组织并分离干细胞的步骤。 细胞粘附蛋白包括哺乳动物脐带胶原,明胶,纤连蛋白,层粘连蛋白或聚-D-赖氨酸。
    • 4. 发明授权
    • 단일염기다형을 포함하는 폴리뉴클레오티드, 그를 포함하는마이크로어레이 및 진단키트, 및 그를 이용한 조기폐경진단방법
    • 包含单核多核苷酸,微阵列和包含其的诊断试剂盒的多核苷酸以及使用该方法诊断原发性卵巢衰竭的方法
    • KR100768685B1
    • 2007-10-19
    • KR1020060039381
    • 2006-05-02
    • 의료법인 성광의료재단
    • 이숙환이정노차광렬정형민조성원곽규범차동현정창조
    • C12N15/11C12N15/10
    • A polynucleotide including single nucleotide polymorphism(SNP) derived from LAMC1 (Laminin, gamma 1) or a complementary polynucleotide thereof is provided to be used as a clinical diagnosis marker of premature ovarian failure(POF). A polynucleotide or a complementary nucleotide thereof is at least one selected from the group consisting of a polynucleotide(b) which consists of more than 10 consecutive DNA sequences, is derived from a DNA sequence described as SEQ ID : NO. 2 and has a 201st base(polymorphism) of C; a polynucleotide(d) which consists of more than 10 consecutive DNA sequences, is derived from a DNA sequence described as SEQ ID : NO. 4 and has a 201st base(polymorphism) of C; a polynucleotide(e) which consists of more than 10 consecutive DNA sequences, is derived from a DNA sequence described as SEQ ID : NO. 5 and has a 222nd base(polymorphism) of T; a polynucleotide(f) which consists of more than 10 consecutive DNA sequences, is derived from a DNA sequence described as SEQ ID : NO. 6 and has a 767th base(polymorphism) of G; a polynucleotide(g) which consists of more than 10 consecutive DNA sequences, is derived from a DNA sequence described as SEQ ID : NO. 7 and has a 767th base(polymorphism) of G; a polynucleotide(j) which consists of more than 10 consecutive DNA sequences, is derived from a DNA sequence described as SEQ ID : NO. 10 and has a 201st base(polymorphism) of A; a polynucleotide(k) which consists of more than 10 consecutive DNA sequences, is derived from a DNA sequence described as SEQ ID : NO. 11 and has a 501st base(polymorphism) of T; and a polynucleotide(l) which consists of more than 10 consecutive DNA sequences, is derived from a DNA sequence described as SEQ ID : NO. 12 and has a 201st base(polymorphism) of T.
    • 提供了包含衍生自LAMC1(层粘连蛋白,γ1)的单核苷酸多态性(SNP)或其互补多核苷酸的多核苷酸以用作早产儿卵巢功能衰竭(POF)的临床诊断标志物。 多核苷酸或其互补核苷酸是选自由多于10个连续DNA序列组成的多核苷酸(b)中的至少一种,衍生自SEQ ID NO:1所示的DNA序列。 2,具有201的碱基(多态性)C; 由多于10个连续DNA序列组成的多核苷酸(d)衍生自SEQ ID NO: 4,具有201的碱基(多态性)C; 由多于10个连续DNA序列组成的多核苷酸(e)衍生自SEQ ID NO: 5,具有T的第222个碱基(多态性) 由多于10个连续DNA序列组成的多核苷酸(f)衍生自SEQ ID NO: 6,具有G的第767位碱基(多态性) 由多于10个连续DNA序列组成的多核苷酸(g)衍生自SEQ ID NO: 7,具有G的第767位碱基(多态性) 由多于10个连续DNA序列组成的多核苷酸(j)衍生自SEQ ID NO: 并具有A的201位碱基(多态性); 由超过10个连续DNA序列组成的多核苷酸(k)衍生自SEQ ID NO: 11,具有501的碱基(多态性); 和由多于10个连续的DNA序列组成的多核苷酸(1)衍生自SEQ ID NO: 12,并具有第201位(多态性)T.
    • 7. 发明公开
    • 세포주입용 주사바늘 및 이를 구비한 주사기
    • 注射针头注射干细胞和注射装置
    • KR1020120042604A
    • 2012-05-03
    • KR1020110020129
    • 2011-03-07
    • 변기현(주)차바이오텍
    • 변기현정형민문성환홍기성
    • A61M5/32A61M5/178A61M5/158
    • A61M5/329A61M5/3291
    • PURPOSE: An injection needle for cell injection and a syringe including thereof are provided to prevent leaking of cell solution which is injected into cardiac muscles by forming an injection needle shaft in a spiral shape. CONSTITUTION: An injection needle for cell injection(10) includes a spiral shaped needle shaft(11). A plurality of openings is formed on side of the injection needle shaft. The needle shaft includes bioabsorbable material in order to decompose within organs. The needle shaft comprises a second shaft of bioabsorbable material which is made of metal and a first shaft. The syringe comprises an injection needle having a spiral shape, an injector barrel which has an injection needle, and a plunger which is inserted into the injector barrel.
    • 目的:提供用于细胞注射的注射针和包括其的注射针,以通过形成螺旋形状的注射针轴来防止注射到心肌中的细胞溶液的泄漏。 构成:用于细胞注射的注射针(10)包括螺旋状的针轴(11)。 在注射针轴的侧面上形成有多个开口。 针轴包括生物可吸收材料,以便在器官内分解。 针轴包括由金属制成的生物可吸收材料的第二轴和第一轴。 注射器包括具有螺旋形状的注射针,具有注射针的注射器筒和插入到注射器筒中的柱塞。
    • 9. 发明授权
    • 인간배아줄기세포 유래 혈관전구세포를 이용한 창상 치료용 이식재 및 창상 치료 방법
    • 使用人类胚胎干细胞衍生的血管生成祖细胞hESC-VAPCs进行伤口愈合的治疗性植入物及其方法
    • KR101045492B1
    • 2011-06-30
    • KR1020080055381
    • 2008-06-12
    • (주)차바이오텍
    • 정형민임좌진문성환김주미
    • A61K35/545A61K9/00
    • A61K35/44
    • 본 발명은 (a)이식을 위한 배아 줄기세포 유래의 혈관전구세포를 배양하는 단계; (b)상기 배양된 배아 줄기세포 유래 혈관전구세포를 포유동물의 피부에 이식하는 단계를 포함하는, 배아 줄기세포 유래 혈관전구세포를 이용한 창상 치료 방법을 제공한다.
      본 발명의 창상 치료 방법은 기존 창상 치료에 효과가 있다고 알려진 혈관전구세포의 새로운 세포 공급원인 인간배아 줄기세포 유래 혈관전구세포를 이용함으로써, 세포 공급원에 제한성을 없앴으며, 제대혈 줄기세포 유래 혈관전구세포 등 종래의 성체 줄기세포 유래 혈관전구세포보다 창상 치료 효율을 크게 향상 시키는 효과가 있다. 또한, 본 발명의 창상 치료 방법에 따르면 이식된 인간배아 줄기세포 유래 혈관전구세포는 혈관 신생을 촉진시켜 상처 치유에 필요한 인자들의 전이를 용이하게 하여, 상처 치유에 필요한 콜라겐의 합성을 증가시켰으며, 새로이 형성된 콜라겐층이 상처 치유를 위해 필요한 기질 세포 및 피부 세포 등이 보다 용이하게 자랄 수 있는 환경을 조성하여, 종래 기술보다 상처 치유 기간을 단축시키는 효과가 있다.
      인간배아 줄기세포, 창상 치료, 인간배아 줄기세포 유래 혈관전구세포